Innate Pharma S.A. (IPHA) Discusses EUR 30 Million Equity Raise, Strategic Partnership and Pipeline Advancement Transcript

SA Transcripts 161.84K Followers Follow Innate Pharma S.A. ( IPHA ) Discusses EUR 30 Million Equity Raise, Strategic Partnership and Pipeline Advancement August 14, 2026 8:00 AM EDT Company Participants Stephanie Cornen - Vice President of Investor Relations, Communication & Commercial Strategy Jonathan Dickinson - CEO & Director Conference Call Participants Daina Graybosch - Leerink Partners LLC, Research Division Swayampakula Ramakanth - H.C. Wainwright & Co, LLC, Research Division Jeet Mukherjee - BTIG, LLC, Research Division Presentation Operator Hello, everyone. Thank you for joining us, and welcome to the Innate Pharma webcast call. [Operator Instructions] I will now hand the conference over to Stephanie Cornen, Vice President of Investor Relations and Communications at Innate Pharma. Please go ahead. Stephanie Cornen Vice President of Investor Relations, Communication & Commercial Strategy Good morning, and good afternoon, everyone. Thank you for joining us for the conference call. Before we begin, I would like to remind everyone that today's presentation includes forward-looking statements based on current expectations. These statements involve risks and uncertainties that could cause actual results to differ materially. With that, I will now hand it over to Jonathan. Jonathan Dickinson CEO & Director Thank you, Stephanie, and thank you, everybody, for joining us this morning in the U.S., this afternoon in Europe to discuss this morning's announcement of Innate Pharma's EUR 30 million equity raise. This week has been a very busy and important week for Innate Pharma, putting in place the critical elements, which allow continued advancement of the strategic agenda, which we announced in September last year. As a reminder, this strategic agenda includes a number of items. First, advancing lacutamab into the confirmatory TELLOMAK-3 Phase III study in cutaneous T-cell lymphoma, which has already been greenlighted by the FDA. Study initiation allows advancement towards the BLA filing for Sézary syndrome under the FDA breakthrough therapy designation once patient recruitment is ongoing. The